

## CNP-38

<b>Cat. No.:</b>	HY-P5127
<b>Molecular Formula:</b>	C <sub>175</sub> H <sub>291</sub> N <sub>55</sub> O <sub>50</sub> S <sub>3</sub>
<b>Molecular Weight:</b>	4061.72
<b>Sequence:</b>	Leu-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bridge: Cys22-Cys38)
<b>Sequence Shortening:</b>	LQEHPNARKYKGANKKGLSKGCFGLKLDRIQSMSGLGC (Disulfide bridge: Cys22-Cys38)
<b>Target:</b>	Angiotensin Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	CNP-38 is a C-type natriuretic peptide <sup>[1]</sup> .								
<b>In Vivo</b>	<p>CNP-38 (s.c., 800 µg/kg, once) reduces blood pressure in male telemetered adult Crl:CD1(ICR) mice<sup>[1]</sup>.            CNP-38 (subcutaneous injections or continuous infusion, 203 µg/kg, daily for 5 weeks) makes the axis and limb bones of mice grow significantly, and the effect of continuous infusion was more obvious<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male FVB mice</td> </tr> <tr> <td>Dosage:</td> <td>203 µg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injections or continuous infusion, daily for 5 weeks</td> </tr> <tr> <td>Result:</td> <td>Resulted in increases of 7.1% in femoral length, 12.2% in tibia length and 25% in spinal length by continuous infusion, while daily subcutaneous administration induced increases of 5.5%, 4% and 11.3%, respectively.</td> </tr> </table>	Animal Model:	Male FVB mice	Dosage:	203 µg/kg	Administration:	Subcutaneous injections or continuous infusion, daily for 5 weeks	Result:	Resulted in increases of 7.1% in femoral length, 12.2% in tibia length and 25% in spinal length by continuous infusion, while daily subcutaneous administration induced increases of 5.5%, 4% and 11.3%, respectively.
Animal Model:	Male FVB mice								
Dosage:	203 µg/kg								
Administration:	Subcutaneous injections or continuous infusion, daily for 5 weeks								
Result:	Resulted in increases of 7.1% in femoral length, 12.2% in tibia length and 25% in spinal length by continuous infusion, while daily subcutaneous administration induced increases of 5.5%, 4% and 11.3%, respectively.								

### REFERENCES

[1]. Vibeke Miller Breinholt, et al. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias. *J Pharmacol Exp Ther.* 2019 Sep;370(3):459-471.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA